Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (2017 - 2025)

Historic Shares Outstanding for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $85.1 million.

  • Sutro Biopharma's Shares Outstanding rose 328.47% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 328.47%. This contributed to the annual value of $82.5 million for FY2024, which is 3526.74% up from last year.
  • Latest data reveals that Sutro Biopharma reported Shares Outstanding of $85.1 million as of Q3 2025, which was up 328.47% from $84.7 million recorded in Q2 2025.
  • Sutro Biopharma's Shares Outstanding's 5-year high stood at $85.1 million during Q3 2025, with a 5-year trough of $46.1 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding was $60.5 million (2023), whereas its average is $63.1 million.
  • The largest annual percentage gain for Sutro Biopharma's Shares Outstanding in the last 5 years was 9848.78% (2021), contrasted with its biggest fall of 125.68% (2021).
  • Sutro Biopharma's Shares Outstanding (Quarter) stood at $46.3 million in 2021, then increased by 24.12% to $57.5 million in 2022, then grew by 6.1% to $61.0 million in 2023, then skyrocketed by 35.27% to $82.5 million in 2024, then rose by 3.12% to $85.1 million in 2025.
  • Its last three reported values are $85.1 million in Q3 2025, $84.7 million for Q2 2025, and $84.3 million during Q1 2025.